Učitavanje...
ONC201: a new treatment option being tested clinically for recurrent glioblastoma
Glioblastoma is an aggressive central nervous system tumor with a 5-year-survival rate of less than 10%. Patients diagnosed with the disease are treated with surgery, radiation and temozolomide chemotherapy. Despite survival benefits, patients eventually relapse. There is a need for new treatments w...
Spremljeno u:
| Izdano u: | Transl Cancer Res |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6117120/ https://ncbi.nlm.nih.gov/pubmed/30175049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tcr.2017.10.03 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|